Sanofi split over possible Bristol merger
The disagreement concerns the Sanofi chairman Jean-Francois Dehecq who backs a transformational deal with Bristol, and the chief executive Gerard Le Fur who believes it is important to
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.